Omada Raises 2026 Revenue and Ebitda Outlook

The Tip Desk · November 11, 2026 · 2 min read

Third-quarter revenue was $91 million, up 34% from a year earlier, as the company lifted full-year revenue guidance to $344 million to $346 million.

Omada Health (OMDA), the virtual between-visit healthcare provider, reported third-quarter revenue of $91 million, up 34% from $68 million a year earlier, and raised its full-year 2026 outlook for both revenue and Adjusted EBITDA.

Year-over-year revenue growth slowed to 34% from 43% in the second quarter and 42% in the first quarter. Total Members reached 1.1 million, up 36% from a year earlier, after 45% growth in the second quarter and 51% in the first. The company said the member increase reflected demand across its integrated cardiometabolic care platform and enrollment momentum in diabetes and hypertension programs.

GAAP gross margin expanded to 76% from 66% in the third quarter of 2025, after 73% in the second quarter and 62% in the first. Non-GAAP gross margin was 78%. Services revenue was $85.1 million and hardware revenue $6.2 million.

The company swung to net income of $7 million, or $0.10 a share diluted, from a net loss of $3 million, or $0.06 a share, a year earlier. Adjusted EBITDA was $12 million, compared with $2 million in the third quarter of 2025. Operating income was $4.8 million.

Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294, after about 2% growth to $284 in the second quarter. Average member tenure grew 10% year over year to approximately 2 years and 4 months, which the company said is roughly an additional 2.5 months in program.

For the year ending December 31, 2026, Omada Health expects revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025. Adjusted EBITDA is expected in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025. The company did not provide an outlook for GAAP net income.

Cash and cash equivalents were $243 million at September 30, 2026.

Co-founder and Chief Executive Officer Sean Duffy said the quarter was the company’s strongest yet, with diabetes and hypertension programs leading growth. In August the company announced that Duffy would become Founder and Executive Chair and President Wei-Li Shao would become chief executive officer on January 1, 2027.